Clinical Trials Directory

Trials / Completed

CompletedNCT03967951

CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms

Status
Completed
Phase
Study type
Observational
Enrollment
70 (actual)
Sponsor
Francesco De Cobelli · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to quantify inter-observer variability in delineating pancreatic neuroendocrine neoplasm (PanNEN) on Computerized Tomography (CT) images and its impact on radiomic features (RF), subsequently to this determination, to use CT texture analysis to predict, histological characteristics of PanNEN on CT scans.

Detailed description

CT imaging is the most widely used modality for studying radiomic features due to its ability to assess tissue density, shape, texture and size before, during and after therapy. To the best of the investigator's knowledge, the impact of inter-observer delineation variability on the reliability of CT RF for PanNEN patients, including Hounsfield unit (HU) values-, shape-, and texture-based features, has not yet been assessed. One this has been determined, an additional evaluation will be conducted to correlate the morphologically observed images with their histopathological characteristics. The ultimate potential objective of this research is to identify and predict characteristics of aggressiveness of PanNEN in CT scans.

Conditions

Interventions

TypeNameDescription
OTHERCT radiomic feature evaluationRadiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated. In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be. Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated.

Timeline

Start date
2019-03-23
Primary completion
2019-05-06
Completion
2019-05-06
First posted
2019-05-30
Last updated
2019-12-26

Locations

2 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT03967951. Inclusion in this directory is not an endorsement.